$1.58
6.51% day before yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US2075231017
Symbol
CNTB

Connect Biopharma Holdings Ltd - ADR Stock price

$1.58
-0.15 8.67% 1M
+0.80 102.56% 6M
+0.20 14.49% YTD
+0.17 12.06% 1Y
+0.37 30.58% 3Y
-15.42 90.71% 5Y
-15.42 90.71% 10Y
-15.42 90.71% 20Y
Nasdaq, Closing price Fri, Sep 26 2025
-0.11 6.51%
ISIN
US2075231017
Symbol
CNTB
Industry

Key metrics

Basic
Market capitalization
$88.0m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$26.1m | $0.0
EBITDA
$-35.3m | -
EBIT
$-35.9m | $-281.5m
Net Income
$-28.5m | -
Free Cash Flow
$-38.9m
Growth (TTM | estimate)
Revenue
- | -100.0%
EBITDA
- | -
EBIT
- | -1,276.7%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
-135.5% | -
EBIT
-137.6%
Net
-109.4% | -
Free Cash Flow
-149.1%
More
EPS
$-0.5
FCF per Share
-
Short interest
0.0%
Employees
62
Rev per Employee
$420.0k
Show more

Is Connect Biopharma Holdings Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

Buy
89%
Hold
11%

Financial data from Connect Biopharma Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
26 26
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
-
87%
- Research and Development Expense 37 37
-
143%
-35 -35
-
-136%
- Depreciation and Amortization 0.53 0.53
-
2%
EBIT (Operating Income) EBIT -36 -36
-
-138%
Net Profit -29 -29
-
-109%

In millions USD.

Don't miss a Thing! We will send you all news about Connect Biopharma Holdings Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral
GlobeNewsWire
24 days ago
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 202...
Neutral
GlobeNewsWire
25 days ago
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has completed the termination of the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in the following upcoming conferences: Cantor Global Healthcare Conference 2025 Form...
More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office Cayman Islands
CEO Barry Quart
Employees 62
Founded 2015
Website www.connectbiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today